anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Solutions of fat-soluble vitamins dispersable in an aqueous medium comprise one or more fat-soluble vitamins, an emulsifier which consists essentially of an acetone-insoluble phosphatide fraction obtained from soya and sufficient water-free water-miscible solvent which is miscible with said vitamin or vitamins, namely acetic acid diethylamide, to render the solutions clear.  The acetic acid diethylamide may be mixed with other water-free organic solvents, e.g. propylene glycol monomethyl ether, dimethyl formamide and 1-methoxy propanol.  Specified fat-soluble vitamins are A, D, E and K and their fat-soluble derivatives, e.g. fatty acid esters such as palmitate.  Optional additions are other emulsifiers and a polymeric substance such as polyvinyl pyrrolidone having emulsion stabilizing properties.  The added emulsifiers are (a) esters of a fatty acid containing 12 to 18 carbon atoms with a polyhydric alcohol, e.g. glycerin monostearate, sorbitan monopalmitate, ascorbyl palmitate and propylene glycol monolaurate; (b) N-alkanol substituted fatty acid amides, e.g. lauric acid-N-hydroxy ethylamide and palmitic acid-N-diethanolamide; and (c) ethylene oxide condensation products, especially polyethylene glycol ethers of m-pentadecyl phenol containing 12 to 60 ethylene oxide units per molecule and of castor oil with 40 mol of ethylene oxide.  The solutions are intended for use as intermediates in the preparation of drugs, e.g. by diluting with water or normal saline solution, or for vitaminization of foods, e.g. milk.
First dose of lubiprostone 24 micrograms or placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately after the last dose of lubiprostone) at 6 PM the evening before the colonoscopy and continued drinking the solution until at least 2 bowel movements were clear yellow or green. All study patients were educated and instructed to observe for clear stool, which was defined as "watery consistency without any solid fecal material or dark liquid stools." Patients were instructed to return the unused PEG solution on the day of colonoscopy. After completing the preparation but before colonoscopy, patients were also required to fill a questionnaire to assess the tolerability of tablets and solution.
Skeletal muscle is essential in generating mechanical force and regulating energy metabolism and body temperature. Pathologies associated with muscle tissue often lead to impaired physical activity and imbalanced metabolism. Recently, ectodysplasin A2 receptor (EDA2R) signaling has been shown to promote muscle loss and glucose intolerance. Upregulated EDA2R expression in muscle tissue was associated with aging, denervation, cancer cachexia, and muscular dystrophies. Here, we describe the roles of EDA2R signaling in muscle pathophysiology, including muscle atrophy, insulin resistance, and aging-related sarcopenia. We also discuss the EDA2R pathway, which involves EDA-A2 as the ligand and nuclear factor (NF)κB-inducing kinase (NIK) as a downstream mediator, and the therapeutic potential of targeting these proteins in the treatment of muscle wasting and metabolic dysfunction.
A comprehensive medication management system is disclosed. The comprehensive medication management system offers a number of compliance related services that may be offered to patients in to improve medication therapy compliance. The system identifies compliance barriers facing individual patents and recommends services designed to overcome those barriers. The system further provides feedback to patients to document their progress. The system proactively identifies patients who may benefit from compliance services and blocks their transactions until the services are explained. The point of sale block may be expanded to other classes of patients so that the transactions of other classes of patients blocked and other messages delivered or some other customized interactions carried out. The medication management system may serve as a central repository of information about a patient's medication treatment program and the medication management system may provide quick and easy access to a patient's entire medication history to facilitate consultations between a pharmacist and the patient. The medication management system may generate lists of tasks for pharmacists to perform in order to deliver the compliance related services to individual patients.
INTRODUCTION: The emergence of novel infectious diseases has amplified the urgent need for effective prevention strategies, especially ones targeting vulnerable populations such as children. Factors such as the high incidence of both emerging and existing infectious diseases, delays in vaccinations, and routine exposure in communal settings heighten children's susceptibility to infections. Despite this pressing need, a comprehensive exploration of research trends in this domain remains lacking. This study aims to address this gap by employing text mining and modeling techniques to conduct a comprehensive analysis of the existing literature, thereby identifying emerging research trends in infectious disease prevention among children.
METHODS: A cross-sectional text mining approach was adopted, focusing on journal articles published between January 1, 2003, and August 31, 2022. These articles, related to infectious disease prevention in children, were sourced from databases such as PubMed, CINAHL, MEDLINE (Ovid), Scopus, and Korean RISS. The data underwent preprocessing using the Natural Language Toolkit (NLTK) in Python, with a semantic network analysis and topic modeling conducted using R software.
RESULTS: The final dataset comprised 509 journal articles extracted from multiple databases. The study began with a word frequency analysis to pinpoint relevant themes, subsequently visualized through a word cloud. Dominant terms encompassed "vaccination," "adolescent," "infant," "parent," "family," "school," "country," "household," "community," "HIV," "HPV," "COVID-19," "influenza," and "diarrhea." The semantic analysis identified "age" as a key term across infection, control, and intervention discussions. Notably, the relationship between "hand" and "handwashing" was prominent, especially in educational contexts linked with "school" and "absence." Latent Dirichlet Allocation (LDA) topic modeling further delineated seven topics related to infectious disease prevention for children, encompassing (1) educational programs, (2) vaccination efforts, (3) family-level responses, (4) care for immunocompromised individuals, (5) country-specific responses, (6) school-based strategies, and (7) persistent threats from established infectious diseases.
CONCLUSION: The study emphasizes the indispensable role of personalized interventions tailored for various child demographics, highlighting the pivotal contributions of both parental guidance and school participation.
CLINICAL RELEVANCE: The study provides insights into the complex public health challenges associated with preventing and managing infectious diseases in children. The insights derived could inform the formulation of evidence-based public health policies, steering practical interventions and fostering interdisciplinary synergy for holistic prevention strategies.
A method of suppressing appetite is disclosed. An amount of wheat bran sufficient to suppress appetite is consumed prior to or with a meal to achieve satiety and desirable weight reduction. Postum®, a coffee-substitute and containing wheat bran as the quantitatively main ingredient, may be used in one embodiment. It may be prepared by dissolving in boiling water as a beverage or adding to a solid or semi-solid food. Consuming Postum® before or with a meal suppresses appetite so that less food is desired during the meal, yet the individual does not feel hungry. Postum® is a natural product and does not contain herbs, botanicals, stimulants, or synthetic components that may be harmful when consumed.
Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
Surgery and endovascular therapy are the primary treatment options for spinal dural arteriovenous fistula (SDAVF). Due to the absence of a consensus regarding which therapy yields a superior outcome, we conducted a comparative analysis of the surgical and endovascular treatment of SDAVF through a multicenter case series and a systematic literature review. Patients with SDAVF, surgically or endovascularly treated at four neurosurgical centers from January 2001 to December 2021, were included in this study. Level of SDAVF, primary treatment modality, baseline and post-procedural neurological status were collected. The primary outcomes were failure, complication rates, and a newly introduced parameter named as therapeutic delay. A systematic review of the literature was performed according to PRISMA-P guidelines. The systematic review identified 511 papers, of which 18 were eligible for analysis, for a total of 814 patients, predominantly male (72%) with a median age of 61 and mainly thoracic SDAVFs (65%). The failure rate was significantly higher for endovascular therapy (20%) compared to surgery (4%) (p < 0.01). Neurological complications were generally rare, with similar rates among the two groups (endovascular 2.9%; surgery 2.6%). Endovascular treatment showed a statistically significantly higher rate of persistent neurological complications than surgical treatment (2.9% versus 0.2%; p < 0.01). Both treatments showed similar rates of clinical improvement based on Aminoff Logue scale score. The multicenter, retrospective study involved 131 patients. The thoracic region was the most frequent location (58%), followed by lumbar (37%). Paraparesis (45%) and back pain (41%) were the most common presenting symptoms, followed by bladder dysfunction (34%) and sensory disturbances (21%). The mean clinical follow-up was 21 months, with all patients followed for at least 12 months. No statistically significant differences were found in demographic and clinical data, lesion characteristics, or outcomes between the two treatment groups. Median pre-treatment Aminoff-Logue score was 2.6, decreasing to 1.4 post-treatment with both treatments. The mean therapeutic delay for surgery and endovascular treatment showed no statistically significant difference. Surgical treatment demonstrated significantly lower failure rates (5% vs. 46%, p < 0.01). In the surgical group, 2 transient neurological (1 epidural hematoma, 1 CSF leak) and 3 non-neurological (3 wound infections) complications were recorded; while 2 permanent neurological (spinal infarcts), and 5 non-neurological (inguinal hematomas) were reported in the endovascular group. According to the literature review and this multicenter clinical series, surgical treatment has a significantly lower failure rate than endovascular treatment. Although the two treatments have similar complication rates, endovascular treatment seems to have a higher rate of persistent neurological complications.
A few cases of anaphylactic/anaphylactoid reactions are reported in the postmarketing use of Vivelle-Dot. Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) are noted.

Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention are reported in the postmarketing use of Vivelle-Dot. Angioedema involving the tongue, glottis, or larynx, may result in airway obstruction. Do not give Vivelle-Dot to any woman who develops angioedema during treatment with Vivelle-Dot.

Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema. Consider whether the benefits of estrogen therapy outweigh the risks in such women.
Erdafitinib, 8 mg, orally, once daily. Dose increase to 9 mg once daily may be considered based on serum phosphate levels and tolerability.
Two double-blind, placebo-controlled clinical trials were conducted in 1,856 healthy adults and adolescents (≥12 years old) with a history of recurrent cold sores. Patients self-initiated therapy at the earliest symptoms and prior to any signs of a cold sore. The majority of patients initiated treatment within 2 hours of onset of symptoms. Patients were randomized to valacyclovir hydrochloride 2 grams twice daily on Day 1 followed by placebo on Day 2, valacyclovir hydrochloride 2 grams twice daily on Day 1 followed by 1 gram twice daily on Day 2, or placebo on Days 1 and 2.

The mean duration of cold sore episodes was about 1 day shorter in treated subjects as compared with placebo. The 2 day regimen did not offer additional benefit over the 1- day regimen.

No significant difference was observed between subjects receiving valacyclovir hydrochloride or placebo in the prevention of progression of cold sore lesions beyond the papular stage.
Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
Disclosed is the use of a composition in preventing and treating alcoholic brain injury, which belongs to the technical field of biomedicine. Provided is the use of a composition in the preparation of a pharmaceutical preparation for preventing and treating alcoholic brain injury. The composition comprises the following components in parts by weight: 10-30 parts of algal polyphenol, 2-6 parts of sodium alginate, 30-55 parts of abalone peptide and 0.5-3 parts of spermidine. The algal polyphenol, which has antioxidant and antibacterial functions, is combined with the abalone peptide, which is rich in multiple nutrients and has multiple biological effects. Animal experiments prove that the composition has a multi-way, multi-target and synergistic effect in preventing and treating alcoholic brain injury. In addition, the composition has good product stability and high bioavailability, and is safe, non-toxic, convenient for administration, free of unpleasant odors and good in terms of compliance.
BACKGROUND: Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01, formulated in the liposomal adjuvant, CAF09b, was safe and able to elicit EVX-01-specific T cell responses in patients with metastatic melanoma. Here, we present results from the dose-escalation part of the study, evaluating the feasibility, safety, efficacy, and immunogenicity of EVX-01 in addition to anti-PD-1 therapy.
METHODS: Patients with metastatic melanoma on anti-PD-1 therapy were treated in three cohorts with increasing vaccine dosages (twofold and fourfold). Tumor-derived neoantigens were selected by the AI platform PIONEER and used in personalized therapeutic cancer peptide vaccines EVX-01. Vaccines were administered at 2-week intervals for a total of three intraperitoneal and three intramuscular injections. The study's primary endpoint was safety and tolerability. Additional endpoints were immunological responses, survival, and objective response rates.
RESULTS: Compared with the base dose level previously reported, no new vaccine-related serious adverse events were observed during dose escalation of EVX-01 in combination with an anti-PD-1 agent given according to local guidelines. Two patients at the third dose level (fourfold dose) developed grade 3 toxicity, most likely related to pembrolizumab. Overall, 8 out of the 12 patients had objective clinical responses (6 partial response (PR) and 2 CR), with all 4 patients at the highest dose level having a CR (1 CR, 3 PR). EVX-01 induced peptide-specific CD4+ and/or CD8+T cell responses in all treated patients, with CD4+T cells as the dominating responses. The magnitude of immune responses measured by IFN-γ ELISpot assay correlated with individual peptide doses. A significant correlation between the PIONEER quality score and induced T cell immunogenicity was detected, while better CRs correlated with both the number of immunogenic EVX-01 peptides and the PIONEER quality score.
CONCLUSION: Immunization with EVX-01-CAF09b in addition to anti-PD-1 therapy was shown to be safe and well tolerated and elicit vaccine neoantigen-specific CD4+and CD8+ T cell responses at all dose levels. In addition, objective tumor responses were observed in 67% of patients. The results encourage further assessment of the antitumor efficacy of EVX-01 in combination with anti-PD-1 therapy.
Conservative kidney management (CKM) is an active treatment for kidney failure (KF) for people who will either not benefit from kidney replacement therapy (KRT), do not wish to pursue KRT, or do not have access to KRT. CKM aims to improve patients' quality-of-life through meticulous attention to symptom management. KF is associated with a high symptom burden globally that is experienced across age, sex, and race with chronic pain being one of the most severe and common symptoms. The delivery of CKM therefore requires the integration of effective pain management strategies. This review will provide a detailed insight into CKM globally and will offer an approach to pain management for people with KF who are receiving CKM. Specifically, this review will provide an overview of the clinical characteristics of people receiving CKM across both high and low resource settings and the epidemiology of pain in this population. While it will provide some high-level considerations for the non-pharmacologic management of pain, it will focus predominantly on pharmacologic approaches. This will include considerations of non-opioid analgesics and strategies for the use of opioids in people receiving CKM. Furthermore, we will explore global disparities in kidney care, CKM, and pain management resources, including access to opioids and will discuss some of the additional challenges faced in low resource settings.
Microplastics (MPs) are defined as plastic particles smaller than 5 mm in size, and nanoplastics (NPs) are those MPs with a particle size of less than 1000 nm or 100 nm. The prevalence of MPs in the environment and human tissues has raised concerns about their potential negative effects on human health. Macrophages are the major defence against foreign substances in the intestine, and can be polarized into two types: the M1 phenotype and the M2 phenotype. However, the effect of NPs on the polarization of macrophages remains unclear. Herein, we selected polystyrene, one of the most plastics in the environment and controlled the particle sizes at 50 nm and 500 nm respectively to study the effects on the polarization of macrophages. We used mouse RAW264.7 cell line models in this macrophage-associated study. Experiments on cell absorption showed that macrophages could quickly ingest polystyrene nanoplastics of both diameters with time-dependent uptake. Compared to the untreated group and 10 μg/mL treatment group, macrophages exposed to 50 μg/mL groups (50 nm and 500 nm) had considerably higher levels of CD86, iNOS, and TNF-α, but decreased levels of aCD206, IL-10, and Arg-1. According to these findings, macrophage M1 and M2 polarization can both be induced and inhibited by 50 μg/mL 50 nm and 500 nm polystyrene nanoplastics. This work provided the first evidence of a possible MPs mode of action with appropriate concentration and size through the production of polarized M1, providing dietary and environmental recommendations for people, particularly those with autoimmune and autoinflammatory illnesses.
A pharmaceutical compsn. adapted for gastro-intestinal resorption comprises a polypeptide (I) and has a relative bioavailability of drug in blood plasma, of at least 160% on administration compared with 100% for administration of (I) alone. Also claimed is a pharmaceutical compsn. adapted for improved gastro-intestinal resorption contg. (I) and (a) a monosaccharide or sugar alcohol and/or (b) a polyoxyalkylene ether (II). (II) may be e.g. polyoxyethylene ether or polyoxyethylene cholesteryl ether. Also claimed is a compsn. comprising xylose and polyoxyethylene ether.
The present invention relates to a compound prescription of a Chinese medicine for comprehensively conditioning functions of the human body, which belongs to the Chinese medicine. The present invention comprises Chinese medicines of 100g of mantis shrimps, 100g of locusts, 50g of grubs, 40g of earthworms, 5g of snakes, 150g of Chinese pines, 100g of safflower seeds, 250g of herba, 250g of fructus cannabis, 100g of blood wood, 300g of oriental wormwood, 250g of pericarpium citri reticulatae, 25g of aweto, 150g of folium pyrrosiae, 100g of wilted whiting, 250g of black beans, 500g of mung beans, 50g of ginger, etc.; the Chinese medicines are dried and pulverized to be mixed and prepared into the present invention. The present invention promotes blood circulation, eliminates toxin and impurities in the human body, can adjust blood and regulate vital energy, and can dredge meridians and vessels; thus, yin and yang of the human body can be balanced, and the purpose of comprehensive conditioning can be achieved. The present invention can be used for treating both manifestation and root cause of diseases, can be used for people who do not have diseases, and can be used for patients; the present invention can be orally taken and can be coated outside, and has the efficiency of treatment and health care. The present invention is mainly suitable for various symptoms, such as stomach diseases, heart diseases, arteriosclerosis, anaemia, hypertension, apoplexy, hepatitis, nephritis, bronchitis, various inflammation, nerve dysfunction, etc.
The present invention is directed to styryl dyes having the formula:whereinD is an electron donating group;Q is an electron acceptor selected from the group consisting of electron acceptors having the formulae:W is an electron accepting group,R3 is selected from the group consisting of substituted or unsubstituted alkyl or substituted or unsubstituted aryl moieties, n is an integer from 0 to 4,A, B, and C are substituents of their rings and are each independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, sulfoalkyl, carboxyalkyl, and hydrogen, andY is a counterionThe present invention discloses media and methods for recording data. A three-dimensional matrix including a plurality of dye molecules, such a styryl dye molecule of the present invention, is provided. A first volume element in the matrix is exposed to actinic radiation for a duration and at an intensity effective to alter detectably a fraction between 0.3 and 0.7 of the dye molecules contained therein. The detectably altered dye molecules are substantially uniformly dispersed in the first volume element. The data storage methods and media of the present invention have approximately 1012 volume elements per square centimeter, and each of the volume elements can store a single bit, digital information of approximately 8 bits, or analog information. The data storage methods and media of the present invention are particularly useful for storing or archiving a series of two-dimensional black and white or color images, such as frames of a movie. Methods for reading data stored in the data storage media of the present invention using confocal microscopy are also disclosed.
BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.